In utero gene therapy: Pioneering diagnostic and therapeutic technologies

Abstract

Advancements in prenatal imaging, molecular diagnostics, and genetic screening have transformed the management of congenital diseases, enabling early identification and treatment in utero. These innovations facilitate medical interventions before clinical symptoms arise, improving outcomes and reducing disease severity. Advanced genetic testing of blood, tissue, and other biological samples, combined with techniques such as fluorescence in situ hybridization and chromosomal microarray analysis, allows precise detection and classification of monogenic, mitochondrial, chromosomal, and multifactorial disorders. Emerging in utero therapies, particularly gene therapy, leverage the fetus's unique developmental properties to provide targeted and minimally invasive treatment for structural and genetic abnormalities. However, key challenges remain, such as ensuring biocompatibility and achieving efficient intracellular transgene delivery. Progress in viral and non-viral delivery systems and advancements in gene editing technologies have shown potential in overcoming these obstacles, paving the way for clinical translation. Nanotechnology further enhances these efforts by providing customizable, stable platforms for stage-specific and tissue-targeted interventions, broadening the scope of successful in utero treatments. Collectively, these advances in prenatal diagnostics and therapeutic strategies present an opportunity to address congenital disorders at their origin, significantly improving longterm health outcomes and quality of life by intervening at the earliest stages of development.